Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Paclitaxel

abstract

  • Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT00542451.).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4313867

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1406281

PubMed ID

  • 25564897

Additional Document Info

start page

  • 134

end page

  • 41

volume

  • 372

number

  • 2